GlassScriptPhysician profile
Jonathan Akanno
NPI 1760680227
$4,859.02
in general payments reported to CMS, 2019-2025
24 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,652 · 2020: $604 · 2021: $423 · 2022: $795 · 2023: $214 · 2024: $65.59 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.96 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,243.90 | 2021-2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $913.18 | 2019-2025 | Breztri |
| Amgen INC. | $330.22 | 2019 | |
| Akcea Therapeutics, INC. | $302.62 | 2019-2020 | |
| Novo Nordisk INC | $275.67 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $256.95 | 2019 | |
| Alkermes, INC. | $217.56 | 2019-2024 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $214.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.43 | 2019 | |
| Glaxosmithkline, LLC. | $130.17 | 2019 | |
| Lilly USA, LLC | $122.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $106.76 | 2019 | |
| Abbvie INC. | $103.36 | 2019 | |
| Allergan, INC. | $95.79 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $85.00 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.11 | 2019-2023 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $43.05 | 2020 | |
| Vanda Pharmaceuticals INC. | $39.51 | 2019 | |
| Thea Pharma INC. | $23.64 | 2025 | Iyuzeh |
| Kowa Pharmaceuticals America, INC. | $21.22 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $19.94 | 2019 | |
| Cranial Technologies, INC | $18.63 | 2024 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $15.91 | 2021 | |
| Therapeuticsmd, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Akanno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.